Ribitol is a small molecule commercialized by BridgeBio Pharma, with a leading Phase III program in Limb-Girdle Muscular Dystrophy. According to Globaldata, it is involved in 3 clinical trials, of which 1 was completed, and 2 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Ribitol’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Ribitol is expected to reach an annual total of $72 mn by 2035 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Ribitol Overview
Ribitol (BBP-418) is under development for the treatment of limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). It acts by restoring glycosylate alpha- dystroglycan (aDG) substrate. It is an oral small molecule therapy.
BridgeBio Pharma Overview
BridgeBio Pharma (BridgeBio) is a commercial-stage biopharmaceutical company that primarily focuses on the discovery, creation, testing, and delivery of transformative medicines. The company’s major products include Acoramidis, a TTR stabilizer for transthyretin amyloidosis (ATTR), and NULIBRY (fosdenopterin), a synthetic cPMP for molybdenum cofactor deficiency (MoCD). BridgeBio’s products are used in the medical industry, specifically in the treatment of various genetic diseases and cancers. The company’s pipeline products include precision cardiorenal, mendelian, precision oncology and gene therapy. Its brands include TRUSELTIQ and NULIBRY. The company operates Canada, the US, France, Germany, Switzerland and the UK. BridgeBio is headquartered in Palo Alto, California, the US.
The company reported revenues of (US Dollars) US$9.3 million for the fiscal year ended December 2023 (FY2023), a decrease of 88% over FY2022. The operating loss of the company was US$607.4 million in FY2023, compared to an operating loss of US$512.2 million in FY2022. The net loss of the company was US$643.2 million in FY2023, compared to a net loss of US$481.2 million in FY2022.
The company reported revenues of US$2.2 million for the second quarter ended June 2024, a decrease of 99% over the previous quarter.
For a complete picture of Ribitol’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
